Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option
April 04, 2012
Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Study Points to Role of ABCB1 Gene Alterations in Plavix-Treated Patients' Cardiovascular AEs
March 17, 2010 / Pharmacogenomics Reporter - PGx Highlights from American College of Cardiology Annual Meeting
April 4, 2012 / Pharmacogenomics Reporter - Medco Study to Gauge Whether PGx-Based Plavix Dosing is as Effective as Higher-Priced Effient
October 21, 2009 / Pharmacogenomics Reporter - Medco to Compare Effient vs. PGx-Guided Plavix in Heart Patients on Prevacid
July 28, 2010 / Pharmacogenomics Reporter - FDA Updates Plavix Label with PGx Data, but Does Not Provide Dosing Recommendations
June 17, 2009 / Pharmacogenomics Reporter